Choroidal Neovascularization Market: Anti-VEGF and AI Advances Fuel Growth to 2034

Subheadline:
Expanding use of anti-VEGF biologics, AI-assisted retinal imaging, and a rising elderly population propel the global choroidal neovascularization (CNV) market to new heights.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72251

Introduction
The Choroidal Neovascularization (CNV) Market is witnessing strong momentum, supported by rapid adoption of anti-VEGF therapies, AI-based diagnostic imaging, and growing prevalence of retinal diseases such as age-related macular degeneration (AMD) and pathological myopia.

Valued at USD 8.2 billion in 2024, the market is forecast to reach USD 14.6 billion by 2034, growing at a CAGR of 5.9% during the period.
As healthcare systems expand ophthalmology infrastructure and invest in tele-retinal screening programs, early detection and treatment outcomes are improving significantly-particularly across North America, Europe, and rapidly urbanizing regions of Asia-Pacific.

Key Players in the Market
The CNV treatment landscape is dominated by pharmaceutical leaders and biotech innovators focused on anti-angiogenic, gene-therapy, and sustained-release ocular delivery technologies.

Key players include:
• Roche Holding AG (Genentech)
• Regeneron Pharmaceuticals, Inc.
• Novartis AG
• Bayer AG
• Samsung Bioepis Co., Ltd.
• Ophthotech Corporation (IVERIC Bio)
• Amgen Inc.
• Kubota Vision Inc.
• Adverum Biotechnologies
• Kodiak Sciences Inc.

These companies are investing in long-acting anti-VEGF biologics, gene-encoded therapies, and biosimilar development to expand affordability and adherence.

Key Events in the Last Five Years
• 2020-2022: Approval and global rollout of Faricimab (Vabysmo, Roche) and Brolucizumab (Beovu, Novartis), offering extended dosing intervals and improved patient compliance.
• 2022-2023: Regeneron expanded trials for Eylea HD (aflibercept 8 mg) with 12-16-week dosing schedules.
• 2023: AI-driven retinal image analytics integrated into large-scale screening programs in Japan and the UK, enhancing early CNV detection.
• 2024: Gene-therapy approaches from Adverum Biotech and Regenxbio advanced into late-stage clinical evaluation for durable VEGF inhibition.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72251/choroidal-neovascularization-market

Market Growth Rate
According to Exactitude Consultancy, the CNV market is expected to maintain steady growth at a CAGR of 5.9% (2025-2034).

Growth is primarily attributed to:
• Rising geriatric population and AMD prevalence.
• Expanding adoption of anti-VEGF biologics and biosimilars.
• Technological progress in optical coherence tomography (OCT) and AI-based image analytics.
• Ongoing shift toward sustained-release delivery platforms that reduce treatment burden.

Market Segments and Growth Analysis
The CNV market is segmented by treatment type, disease indication, and region.
By Treatment Type:
• Anti-VEGF Agents (Ranibizumab, Aflibercept, Bevacizumab, Brolucizumab)
• Corticosteroids
• Photodynamic Therapy (PDT)
• Gene & Cell-based Therapies
• Combination Therapies

By Disease Indication:
• Age-Related Macular Degeneration (AMD)
• Pathologic Myopia
• Ocular Histoplasmosis Syndrome
• Others

By Region:
• North America: Dominates the market with strong R&D activity and high biologic adoption rates.
• Europe: Expanding biosimilar approvals and government reimbursement programs.
• Asia Pacific: Rapid growth in Japan, China, and India through tele-ophthalmology programs.
• Latin America & MEA: Improving access to affordable biosimilars and mobile screening services.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72251

Key Market Drivers
1. Advancements in Anti-VEGF Therapeutics:
Longer-acting, dual-pathway biologics reduce injection frequency and improve adherence.
2. Aging Global Population:
Rising AMD incidence among people aged 60+ significantly increases market demand.
3. AI-Powered Retinal Imaging:
Machine-learning tools enhance screening accuracy, reducing vision-loss risk through early detection.
4. Growing Use of Biosimilars:
Cost-effective alternatives are accelerating access in emerging economies.

Recent Developments
• 2023: Roche launched Vabysmo in additional Asian and Latin American markets, strengthening global distribution.
• 2024: Regeneron received FDA approval for Eylea HD, offering extended dosing intervals.
• 2024: Kodiak Sciences reported positive results for its Tarzayan (KSI-301) long-acting antibody biopolymer conjugate.
• 2024: Regenxbio began late-stage trials for RGX-314, a one-time sub-retinal gene therapy for wet AMD and CNV.

Expert Insight
"We are at a turning point in retinal care. The combination of AI-driven diagnostics, gene-based therapies, and long-acting anti-VEGF agents will redefine how clinicians manage CNV and prevent vision loss globally,"
- Dr. Elena Moretti, Senior Ophthalmologist, University of Milan.

Conclusion
The Choroidal Neovascularization Market stands at the forefront of ophthalmic innovation.
As biotechnology and artificial intelligence converge, patients are gaining access to more effective, less burdensome, and increasingly affordable treatment options.

With robust R&D pipelines, expanding healthcare access, and digital diagnostic integration, the CNV market is expected to sustain strong growth through 2034, significantly reducing global vision impairment rates.

This report is also available in the following languages : Japanese (脈絡膜血管新生市場), Korean (맥락막 신생혈관 시장), Chinese (脉络膜新生血管市场), French (Marché de la néovascularisation choroïdienne), German (Markt für choroidale Neovaskularisation), and Italian (Mercato della neovascolarizzazione coroidale), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72251

Our More Reports:

Medical Robotics Market
https://exactitudeconsultancy.com/reports/73445/medical-robotics-market

Drug Device Combination Products Market
https://exactitudeconsultancy.com/reports/73455/drug-device-combination-products-market

Vaccine Delivery Devices Market
https://exactitudeconsultancy.com/reports/73477/vaccine-delivery-devices-market

Amyloidosis Clinical Market
https://exactitudeconsultancy.com/reports/73634/amyloidosis-clinical-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.